As investors pile into psychedelics, idealism gives way to pharma eco
As investors pile into psychedelics, idealism gives way to pharma eco
Money is pouring into the psychedelic medicine industry, with dozens of startups vying to sell mind-expanding drugs like magic mushrooms and ayahuasca. Wall Street's exuberance for hallucinogens has rankled advocates, who fear that these drugs will become expensive, specialty medications controlled by a handful of biotech companies rather than being widely available for mental health.
Money is pouring into the psychedelic medicine industry, with dozens of startups vying to sell mind-expanding drugs like magic mushrooms and ayahuasca. Wall Street's exuberance for hallucinogens has rankled advocates, who fear that these drugs will become expensive, specialty medications controlled by a handful of biotech companies rather than being widely available for mental health.
We use cookies to improve your experience on our site and to show you relevant advertising. To find out more, read our updated privacy policy and cookie policy
Through RSS Feeds 
Money is pouring into the psychedelic medicine industry, with dozens of startups vying to sell mind-expanding drugs like magic mushrooms and ayahuasca. Wall Street's exuberance for hallucinogens has rankled advocates, who fear that these drugs will become expensive, specialty medications controlled by a handful of biotech companies rather than being widely available for mental health. 
